PTC Therapeutics, Inc. (PTCT) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Warren, NJ, United States. The current CEO is Matthew Klein.
PTCT has IPO date of 2013-06-20, 939 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $6.04B.
PTC Therapeutics, Inc. is a biopharmaceutical company headquartered in South Plainfield, New Jersey, dedicated to discovering, developing, and commercializing medicines for patients with rare disorders. The company's commercial portfolio includes Translarna and Emflaza for Duchenne muscular dystrophy treatment across the United States, European Economic Area, Brazil, and Russia; Tegsedi and Waylivra for rare disease treatment in Latin America and the Caribbean; and Evrysdi for spinal muscular atrophy in Brazil. PTC Therapeutics maintains a robust pipeline of candidates in clinical, pre-clinical, and research stages, including PTC518 for Huntington's disease, supported by its proprietary splicing platform technology. The company collaborates with leading partners including Roche and the Spinal Muscular Atrophy Foundation to advance drug discovery and commercialization efforts in regenerative medicine and rare disease treatment globally.
